Discontinuation Recommendations for GLP-1 Receptor Agonists Prior to Colonoscopy: A Randomized Controlled Trial in Taiwan.

This study aims to evaluate the impact of different discontinuation intervals of GLP-1 receptor agonists prior to colonoscopy on bowel preparation quality and the need for repeat colonoscopy, in order to establish appropriate discontinuation recommendations.

Inclusion Criteria: * Inclusion Criteria for non GLP-1 user: * Individuals who are scheduled to undergo total colonoscopy for any reasons * Age between 18 to 70 years. * ECOG Performance status is 0 or 1. * Written consent to participate in the study has been obtained. * Outpatient department patient * Stop at least 3 days if current using medications that promote or inhibit gastrointestinal motility. Exclusion Criteria: * • Presence of severe comorbid conditions that preclude the safe performance of colonoscopy (e.g., unstable angina, recent myocardial infarction, decompensated heart failure, chronic respiratory disease, or bleeding diathesis). * History of prior gastric, small bowel, or colorectal segmental resection (patients with isolated appendectomy are eligible). * Family history of hereditary colorectal cancer syndromes. * Current or prior diagnosis of inflammatory bowel disease. * Known colorectal polyposis syndromes. * Any other condition deemed inappropriate for study participation at the discretion of the treating physician. * Body mass index (BMI) \> 40 kg/m². * Diagnosis of liver cirrhosis. * Diagnosis of Parkinson's disease. * Diagnosis of dementia. * Use of tricyclic antidepressants or opioid medications for more than 3 months.